DEBN sp. z o.o.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2017-07-31
Share capital
51,100.00 PLN
Activity description

DEBN develops a medical device for prostate biopsy, consisting of a biopsy needle and an anesthetic needle with a polymer coating that releases a drug directly into the prostate. The first model contains polyvinyl alcohol and amikacin; the device is intended to potentially reduce infections associated with transrectal biopsy.

Registered address
ul. Szafarnia 11/F8, 80-755 Gdańsk, Poland
Website
Email
Social media

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 1 of 6 financial statements was filed late (for 2021, 76 days late).

  • 2025not filed
  • 202430/06/2025
  • 202313/07/2024
  • 202230/06/2023
  • 202129/09/2022
  • 202028/09/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.

Top 34%
Top 34%
Voivodeship · Pomorskie14,777 / 32,702
Top 45%
Country · Poland222,943 / 496,474
Top 45%

Results vs industry

Revenue
This companyUSD 247.95kMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -37.73kMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 281.66kMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 2.00mMedianUSD 281.58kAverageUSD 8.35m

Offer

  • Biopsy needles
  • Anaesthetic needles
  • Amikacin coatings
  • Biopsy needle kits

Websites

  • debn.euDRUG-ELUTING BIOPSY NEEDLE
    LiteSpeed

Authorized Representatives

Artur Mariusz Gibas age 47 – Management Board Member
Marcin Jan Sieczkowski age 42 – President of the Management Board
Michał Łukasz Krużycki age 46 – Management Board Member

Manner of representation

The company will be represented by two members of the management board jointly, with the proviso that, if a member of the management board is appointed by Alfabeat Alfa spółka z ograniczoną odpowiedzialnością spółka komandytowo-akcyjna, the submission of declarations of will on behalf of the company will always require the joint action of the Vice-President of the Management Board.

Ownership

OwnerSharesShare valueStake
50$675.314.8924%
Cet Advisors Limited
25$337.662.4462%
130$1,755.8112.7202%
90$1,215.568.8063%
100$1,350.629.7847%
450$6,077.8044.0313%
130$1,755.8112.7202%
Mariusz Trus
47$634.794.5987%

The articles of association restrict share transfers (type of consent unspecified).

Beneficial owners

Person

Capital group

The company belongs to the CET Advisors Limited (United Kingdom) group, which is its direct owner.

Bank accounts

Registered as a VAT taxpayer on 2017-08-04.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

9 public aid cases recorded, with a total value of $1,204,643.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$8,512
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,282
Aid for research and development projects: experimental development
$456.4K

European Funds

ProjectEU co-financing
Clinical evaluation of DEBN (Drug-Eluting Biopsy Needle) as a new method of antibacterial prophylaxis in patients undergoing transrectal prostate biopsy.
$844.9K

Competitors

Name
Prolab sp. z o.o.
Inoris Medical sp. z o.o.
Salon Ortopedyczny Or-Tech sp. z o.o.
Medical Inventi S.A.
Mek-Orto sp. z o.o.
Fiomex sp. z o.o.
Part-Med sp. z o.o.
Cabiomede sp. z o.o.
Orto Nova sp. z o.o.
AUG Medical sp. z o.o.

Change history

DateEvent
2024-10-21Share capital increase
2024-05-28Share capital increase
2024-03-11Share capital increase
2023-12-29Share capital increase
2023-12-11Share capital increase

FAQ

Last updated: 2026-04-24